Latest News of ANVS
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?
By Yahoo! Finance |
3 days ago
Investing in unprofitable businesses can be profitable, but risky due to potential cash burn issues. Annovis Bio (NYSE: ANVS) had a short cash runway of 7 months in September 2024, with a cash burn of...
Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders
By Yahoo! Finance |
2 months ago
Retail investors own a majority stake of 56% in Annovis Bio, giving them significant influence over management decisions. Institutional investors also hold a portion, indicating confidence in the comp...
Annovis Bio, Inc. (ANVS) Stock Price, News, Quote & History
By Yahoo! Finance |
4 months ago
Annovis Bio is a drug platform company working on treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. They have lead candidates in various stages of clinical trials, aiming to ...
-
Annovis Bio, Inc. (ANVS) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 4 months agoAnnovis Bio's Phase III Parkinson's study shows promising results with buntanetap treatment, leading to improvements in UPDRS and cognition....
-
ANVS Stock Price | Annovis Bio Inc. Stock Quote (U.S.: NYSE) | MarketWatch
By MarketWatch | 4 months agoAnnovis Bio, Inc. is a drug platform company developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Their lead candidate, Buntanetap, targets AD, PD, and other neurodeg...